New study assessing sponsor and CRO experience, practices and improvement areas associated with investigative site identification, feasibility, selection and study startup.
Tufts Center for the Study of Drug Development (CSDD) presents the findings of a new study among sponsors and CROs assessing the end-to-end process of finding, evaluating, selecting and activating investigative sites. Building on the 2012 ‘Startup Time And Readiness Tracking’ (START) study on site activation, this new study provides a more extensive and in-depth look at sponsor and CRO experience managing the entire process.
The study also assesses current levels of satisfaction with how various tasks are handled; cycle times associated with specific activities; perceived barriers; areas where improvement opportunities exist; and the impact of investments in technology and management models.
The webinar will discuss the implications of the results and highlight key insights for sponsors and CROs to optimize their investigative site management practices.
This webinar is applicable to:
- Sponsor and CRO roles responsible for site identification, feasibility assessment and selection
- Sponsor and CRO roles responsible for site activation
- Sponsor and CRO roles responsible for collecting and evaluating site and study metrics
Ken Getz, Director of Sponsored Research Programs & Associate Professor, Tufts CSDD
Mr. Getz is an internationally recognized expert on R&D and clinical trial management practices and trends, the global investigative site landscape, site management and patient recruitment and retention practices, and the worldwide market for outsourcing clinical research functions. Mr. Getzâ€™s research studies on protocol design complexity and clinical research efficiency and effectiveness, conducted over the past two decades, are considered by many in the research-based life sciences industry to be pioneering work. His 20+ years of original research benchmarking R&D management practices, global outsourcing and the investigative site landscape have contributed to industry-wide understanding of these critical markets and to improvements in management strategy and execution.Message Presenter
Beth Harper, President, Clinical Performance Partners
Beth is the President of Clinical Performance Partners, Inc., a clinical research consulting firm specializing in enrollment and site performance management and facilitating productive sponsor-site relationships. Beth leverages her 30 years of site, SMO, CRO, Pharma, Consulting, Training and Service Provider experiences, both domestically and internationally, to identify solutions for optimizing the clinical trials process.Message Presenter
Patricia Smith, Business Architect, goBalto
Patricia has over 20 years of experience in the health care sector, with a focus on Study Startup, including clinical trial agreement (CTA) negotiation and finalization, per subject costing development, global startup oversight and management, and global transparency compliance.Message Presenter
What You Will Learn
Senior level professionals involved in:
- Clinical Operations
- Regulatory Compliance
- Project Management
- Regulatory Affairs
goBalto is the industry leader in cloud-based study startup software for the global life sciences industry, offering the only complete end-to-end platform for starting clinical trials, from site identification, feasibility assessment and selection through to activation, with comprehensive metrics to track adherence to timelines and budget. Committed to accelerating clinical trials through innovation, product excellence, and customer success, goBalto works with over half of top 20 Pharma and top 10 CROs. Our customers include: Covance, CMIC HOLDINGS, Genentech Roche, ICON, INC Research, Novartis and PSI CRO. goBalto is headquartered in San Francisco, with offices in Pennsylvania and Singapore. For more information, visit www.gobalto.com.